The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1760
August 3, 2026
View Complete Issue         Table of Contents 2019 
Sibeprenlimab (Voyxact) for Primary Immunoglobulin A Nephropathy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Sibeprenlimab (Voyxact) for Primary Immunoglobulin A Nephropathy
August 3, 2026 (Issue: 1760)
Sibeprenlimab (Voyxact – Otsuka), a subcutaneously injected cytokine A proliferation-inducing ligand (APRIL) blocker, has been granted accelerated approval by the FDA to reduce proteinuria in adults with primary immunoglobulin A nephropathy...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Sibeprenlimab (Voyxact) for Primary Immunoglobulin A Nephropathy
Article code: 1760d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.